Boston Scientific stock
Price history
−56.85% over the period1 year: from $101.76 (November 17, 2025) to $43.91 (November 16, 2026), −56.85%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $43.91 |
| October 30, 2026 | $41.98 |
| September 30, 2026 | $43.65 |
| August 31, 2026 | $48.30 |
| July 31, 2026 | $46.73 |
| June 30, 2026 | $42.68 |
| May 29, 2026 | $48.31 |
| April 30, 2026 | $57.61 |
| March 31, 2026 | $62.75 |
| February 27, 2026 | $76.85 |
| January 30, 2026 | $93.53 |
| December 31, 2025 | $95.35 |
| November 28, 2025 | $101.58 |
| November 17, 2025 | $101.76 |
At a glance
The company
Develops and markets medical devices for interventional procedures in gastroenterology, cardiology, neurology, urology and oncology
Latest results
Quarter to September 30, 2026 · EPS $0.73 (estimate $0.75)
TickerLandia's take on Boston Scientific
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 23 vs a median of 58 over its last 8 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 19 vs 31 (−40%) in a group of 11.
- Strong point: Profitability (65/100 in its group). Weak point: Market momentum (13/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−57.25% from the 52-week high
Analysts · 31 analysts
Average target$49.60+12.96% vs. price
Buy 19 · Hold 12 · Sell 0 · Buy
TickerLandia Fingerprint: Boston Scientific
Compared with similar companies: very weak momentum.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow24
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 18.7 9 EV/EBITDA 13.6 25 Forward P/E 14.2 15 Price/book 2.51 27 Price/sales 3.05 44 Profitabilityhigh65
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 19.6% 73 Net margin 16.6% 85 ROA 5.9% 40 Gross margin 68.0% 66 ROE 14.1% 60 Earnings stabilityaverage47
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.1% 37 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthaverage41
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −21.50% 24 Average revenue growth (3 years) +16.54% 85 Revenue growth (year over year) +1.40% 15 Financial strengthlow37
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.87 26 Current ratio 1.37 27 Interest coverage 11.4 42 Debt/equitycounts in reverse: lower means more financial strength 0.46 53 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak13
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −57.76% 1 Relative strength (3 months) −11.53% 20 Relative strength (6 months) −17.73% 17 Distance from 200-day average −18.11% 12 Riskhigh62
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 60.4% 94 Volatility (60 days) 38.2% 60 Beta (1 year) 0.28 30
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Boston Scientific is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Boston Scientific's P/E today is 22.6, below the median of its last 8 fiscal years (57.8; between 13.6 and 102.8 from 2016 to 2025). Boston Scientific's P/E (trailing 12 months): 18.7, −40% against the median of a group of 11 similar companies (31.4).
Compared with 11 similar companies
| Metric | Boston Scientific | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 18.7 | Low | |
| Forward P/E | 14.2 | Low | |
| Operating margin | 19.6% | Middle | |
| ROE | 14.1% | Middle | |
| Debt/equity | 0.46 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Boston Scientific. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$5.44B
Latest quarter · Q2 2026
Net income
$907M
Latest quarter · Q2 2026
Quarterly net margin
16.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $64.27B
- P/E
- 18.7
- EPS
- $2.37
- Volume
- 9.7M
- Daily trading
- €800.7M
- Dividend yield
- 0.00%
How Boston Scientific is changing
All resultsRevenue grew 15.2% a year on average over the last 5 years
Operating margin rose from 13.0% to 18.0%
Profits turn into cash: free cash flow equal to 128% of net income
Returns
Boston Scientific returns
$1,000 invested in Boston Scientific 5 years ago, on November 16, 2021, would be worth $1,060 today: +6.01% in total, +1.17% per year. This is the price return only: dividends are excluded.
| Period | Boston Scientific | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −1.08% | −3.12% | $989 |
| 6 months | −16.65% | +2.07% | $834 |
| Year to date | −53.95% | +10.46% | $461 |
| 1 year | −56.85% | +13.33% | $432 |
| 3 years | −19.68% | +67.73% | $803 |
| 5 years | +6.01% | +60.86% | $1,060 |
| 10 years | +105.57% | +247.35% | $2,056 |
Over the last 6 months it has done better than 10% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Boston Scientific: technical analysis
Boston Scientific is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 59.4% below its all-time closing high ($108.14, September 8, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 49
- Between 30 and 70
- vs 200-session average
- −18.53%
Support and resistance
Price areas where Boston Scientific has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$49.90+13.64%2 touches, last on September 2, 2026
- Resistance$47.07+7.20%2 touches, last on November 4, 2026
- Resistance$46.09+4.96%3 touches, last on October 23, 2026
- Last price$43.91
- Support$42.31−3.65%6 touches, last on October 8, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.27
- Volatility (60 sessions, annualised)
- 38.0%
- Largest fall in the last year
- −59.14%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Boston Scientific: seasonality
Average monthly price change over 35 years
Over the last 35 years, the strongest month for Boston Scientific has been January: +5.19% on average, positive in 21 years out of 34. The weakest has been September: −2.74% on average, positive in 13 years out of 35. November, the current month, has been positive in 16 years out of 34 (−1.04% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.19% | +6.93% | 21 of 34 |
| February | −0.14% | +0.58% | 18 of 34 |
| March | +1.94% | +0.35% | 19 of 34 |
| April | +1.57% | +3.18% | 22 of 34 |
| May | +1.51% | +2.03% | 20 of 34 |
| June | +0.14% | −0.33% | 17 of 35 |
| July | +2.12% | +3.49% | 22 of 35 |
| August | +0.42% | −0.99% | 16 of 35 |
| September | −2.74% | −3.90% | 13 of 35 |
| October | −0.01% | −0.43% | 16 of 35 |
| November | −1.04% | −0.19% | 16 of 34 |
| December | +3.63% | +3.19% | 26 of 34 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Boston Scientific and its competitors
Boston Scientific organizes its medical devices into two segments, MedSurg and Cardiovascular, serving interventional specialties worldwide. The MedSurg range includes gastrointestinal tools such as biliary stent systems and SpyGlass single-use scopes, urological products such as ureteral stents and holmium laser systems, and spinal cord stimulators and deep brain stimulation systems for movement disorders and chronic pain.
- Headquarters
- Marlborough, United States
- Employees
- 59,000
- Founded
- 1979
- Chief executive
- Michael Mahoney
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Boston ScientificBSX | $64.27B | 19.6% | 18.7 | −16.65% |
| Edwards LifesciencesEW | $61.61B | 28.8% | 61.6 | +31.31% |
| GE HealthCare TechnologiesGEHC | $37.8B | 13.8% | 17.7 | +37.99% |
| StrykerSYK | $117.88B | 24.0% | 33.0 | +1.41% |
| MedtronicMDT | $132.22B | 20.1% | 25.4 | +35.90% |
| DexComDXCM | $31.08B | 24.0% | 32.8 | +33.33% |
Same industry or related industries, similar size. Compare Boston Scientific with its competitors · Full profile
